[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0311747A - Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease - Google Patents

Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease

Info

Publication number
BR0311747A
BR0311747A BR0311747-2A BR0311747A BR0311747A BR 0311747 A BR0311747 A BR 0311747A BR 0311747 A BR0311747 A BR 0311747A BR 0311747 A BR0311747 A BR 0311747A
Authority
BR
Brazil
Prior art keywords
composition
kit
treating disease
pharmaceutical composition
multiple dose
Prior art date
Application number
BR0311747-2A
Other languages
Portuguese (pt)
Inventor
Jonathan W Nyce
Cynthia B Robinson
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Publication of BR0311747A publication Critical patent/BR0311747A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, FORMA DE DOSE SIMPLES OU DE MúLTIPLAS DOSES DA COMPOSIçãO, KIT, E, MéTODO PARA TRATAR DOENçA". Uma composição farmacêutica ou veterinária, compreendendo um não-corticosteróide e/ou seus sais e um agente antimuscarínico (anticolinérgico) e/ou seus sais farmacêutica ou veterinariamente aceitáveis. A composição é provida em várias formulações e na forma de um kit. Os produtos desta patente são úteis na profilaxia e tratamento de várias doenças respiratórias, dos pulmões e malignas."PHARMACEUTICAL COMPOSITION, FORMS OF SIMPLE DOSE OR FOR MULTIPLE DOSES OF COMPOSITION, KIT, AND METHOD FOR TREATING DISEASE". A pharmaceutical or veterinary composition comprising a non-corticosteroid and / or salts thereof and an antimuscarinic (anticholinergic) agent and / or pharmaceutically or veterinarily acceptable salts thereof. The composition is provided in various formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases.

BR0311747-2A 2002-06-12 2003-06-12 Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease BR0311747A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38817002P 2002-06-12 2002-06-12
PCT/US2003/018967 WO2004014293A2 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids

Publications (1)

Publication Number Publication Date
BR0311747A true BR0311747A (en) 2005-06-07

Family

ID=31715648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311747-2A BR0311747A (en) 2002-06-12 2003-06-12 Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease

Country Status (10)

Country Link
EP (1) EP1511500A4 (en)
JP (1) JP2006504666A (en)
KR (1) KR20060011783A (en)
CN (2) CN101700247A (en)
AU (1) AU2003276837B2 (en)
BR (1) BR0311747A (en)
CA (1) CA2487399A1 (en)
IL (1) IL165093A0 (en)
MX (1) MXPA04012410A (en)
WO (1) WO2004014293A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
JP2009504604A (en) * 2005-08-06 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of tiotropium salt in the treatment of severe persistent asthma
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
JP5873012B2 (en) * 2009-05-29 2016-03-01 パール セラピューティクス，インコーポレイテッド Compositions for respiratory delivery of active agents and related methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MY178819A (en) 2013-03-15 2020-10-20 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3847141A1 (en) * 2018-09-07 2021-07-14 Allied Mineral Products, LLC Dry refractory compositions with reduced levels of respirable crystalline silica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
JP3009924B2 (en) * 1992-12-09 2000-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Stabilized medical aerosol formulation
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
IL149984A0 (en) * 2000-10-12 2002-12-01 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
CA2487399A1 (en) 2004-02-19
EP1511500A2 (en) 2005-03-09
CN101700247A (en) 2010-05-05
AU2003276837A2 (en) 2004-02-25
IL165093A0 (en) 2005-12-18
WO2004014293A2 (en) 2004-02-19
JP2006504666A (en) 2006-02-09
CN1674918A (en) 2005-09-28
EP1511500A4 (en) 2009-04-29
AU2003276837B2 (en) 2006-07-20
MXPA04012410A (en) 2005-10-19
AU2003276837A1 (en) 2004-02-25
KR20060011783A (en) 2006-02-03
WO2004014293A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
AR013506A1 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO BE USED IN THE TREATMENT OF DISEASES OF PULMONARCHRONIC OBSTRUCTION AND OF A KIT INCLUDING FORMOTEROL OR A SALT OR SOLVATE OF THE SAME AND BUDESONIDE
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BRPI0317463B8 (en) compound, pharmaceutical composition comprising the same and use of said compound in the preparation of a medicament for treating a transthyretin amyloid disease
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
BR0207024A (en) Fast-acting drug to treat sexual dysfunction
BR0311747A (en) Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease
BRPI0408256A (en) compound, methods of treating a human or animal by limiting cell replication, suffering from cancer, suffering from a neoplastic disease, and suffering from proliferative diseases, use of a compound, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof
BRPI0418026A (en) phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases
BR0315337A (en) Compound, pharmaceutical formulation, and method for treating cancer
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
NO20044751L (en) Preparation and Method of Dosing Liposomes of Specific Sizes to Treat or Prevent Disease
BR0312000A (en) Compounds, pharmaceutical compositions, method for treating or prophylaxis of diseases, and use of the compounds
BR0107983A (en) Use of pramipexole for the treatment of addiction disorders
AR119158A1 (en) HEREDITARY ANGIOEDEMA TREATMENTS
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
BR0313718A (en) Compound, process for the preparation thereof, pharmaceutical composition, methods for treating a human or animal subject suffering from a condition which is cox-2 mediated and for treating a human or animal subject suffering from an inflammatory disorder, and, use of a compound
BR0308108A (en) Compounds; process for the preparation of compound; pharmaceutical composition comprising the same, use of compounds and method of treatment and prophylaxis of diseases and obesity
BR0314261A (en) Compounds, process of preparing a compound, pharmaceutical composition comprising the same, use of a compound, method for treating and / or prophylaxis of diseases and use and / or method of treatment
BR0016291A (en) Compound, use of it, methods for inhibiting transient lower esophageal sphincter relaxation, for the treatment of gastroesophageal reflux disease, regurgitation in babies, nociception, emesis, dyspepsia, ibs, hiccups, cocaine addiction, pain, cough , eructation, asthma related or not to fat, and pharmaceutical formulation
BR0313411A (en) Use of reboxetine for heat wave treatment
BR0309114A (en) Use of particulate carbohydrates in dry powder pharmaceutical compositions, dry powder pharmaceutical composition for inhalation therapy, method of treatment or prophylaxis of respiratory disorders, use of a dry powder pharmaceutical composition, inhalation device, and drug packaging
BR0313278A (en) Compounds, process for the preparation of a compound, pharmaceutical composition comprising the same and its use, method for treating and prophylaxis of diseases and obesity and use of the compounds
BR0207866A (en) Use of flumazenil in the preparation of a drug for the treatment of cocaine addiction
BR0017329A (en) Pharmaceutical formulation of a medicament, use of melatonin in the manufacture of a medicament, and method for preventing or treating symptoms of tardive dyskinesia in a patient using such medicament.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/704, A61P 11/00

Ipc: A61K 31/704 (2011.01), A61P 11/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.